<DOC>
	<DOC>NCT00056693</DOC>
	<brief_summary>To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.</brief_summary>
	<brief_title>Treatment With SU11248 in Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically or cytologically proven diagnosis of carcinoid tumor or pancreatic islet cell tumor. Evidence of unidimensionally measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST). ECOG performance status 0 or 1 Diagnosis of smallcell carcinoma, pheochromocytoma/paraganglioma, Merkel cell carcinoma, or any other second malignancy within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri. Prior treatment with any tyrosine kinase inhibitors or antiVEGF angiogenic inhibitors. Prior treatment with nonVEGFtargeted angiogenic inhibitors is permitted.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Neuroendocrine tumor, advanced disease, sunitinib, Phase 2</keyword>
</DOC>